Goldman Sachs
VNRX icon

Goldman Sachs’s VolitionRx Ltd VNRX Stock Holding History

Goldman Sachs’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-591
Closed -$46K – 6381
2020
Q4 		$46K Sell
591
-2,311
-80% -$159K ﹤0.01% 5390
2020
Q3 		$186K Sell
2,902
-15
-0.5% -$1.02K ﹤0.01% 4940
2020
Q2 		$227K Buy
2,917
+238
+9% +$17.2K ﹤0.01% 4742
2020
Q1 		$167K Buy
+2,679
New +$223K ﹤0.01% 4763
2016
Q3 		– Sell
-969
Closed -$61K – 7203
2016
Q2 		$61K Sell
969
-100
-9% -$6.9K ﹤0.01% 6347
2016
Q1 		$76K Buy
1,069
+472
+79% +$35.4K ﹤0.01% 6221
2015
Q4 		$54K Sell
597
-1,697
-74% -$144K ﹤0.01% 6500
2015
Q3 		$206K Buy
+2,294
New +$176K ﹤0.01% 6000

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Goldman Sachs's VNRX Position: Q1 2021 in Review

Goldman Sachs sold out of VolitionRx Ltd (VNRX) in Q1 2021, closing a stake of 591 shares — an estimated $46K sold.

Goldman Sachs first reported a position in VNRX in Q3 2015 and held it in 8 quarters. The position peaked at $227K in Q2 2020. 57 funds tracked by Wall St. Rank hold VNRX as of Q1 2021.

  • Goldman Sachs reported no remaining VolitionRx Ltd position as of Q1 2021 after selling out during the quarter.
  • Goldman Sachs sold 591 VolitionRx Ltd shares in Q1 2021, an estimated $46K.
  • Goldman Sachs first reported a position in VolitionRx Ltd in Q3 2015 and held it in 8 quarters.
  • Goldman Sachs's VolitionRx Ltd position peaked at $227K in Q2 2020.
  • 57 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.